Amicus Therapeutics Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy Study

Amicus Therapeutics FOLD, today announced preliminary results from an ongoing, open-label Phase 2 drug-drug interaction study to evaluate the safety and pharmacokinetic effects of two doses of migalastat HCl (150 mg and 450 mg) co-administered with ERT (agalsidase beta or agalsidase alfa) in up to 24 males diagnosed with Fabry disease.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!